INTARCIA THERAPEUTICS
Intarcia Therapeutics is a biopharmaceutical company that develops therapies for diseases that require long-term chronic treatment. It offers DUROS, a drug delivery platform that stabilizes and delivers therapeutic proteins and peptides. Intarcia Therapeutics' products include OMEGA DUROS, an interferon delivery device for treating Hepatitis C and ITCA 650, a delivery device that provides type 2 diabetes patients with long-term steady state dosing of an incretin mimetic therapy. Additionally, it develops programs for treating obesity. David Franklin, James M. Ahlers, and Thomas Alessi founded BioMedicines in 1997 that became Intarcia Therapeutics in September 2004. Its headquarters is in Hayward in California with an additional office in Mountain View in California.
INTARCIA THERAPEUTICS
Industry:
Biotechnology Health Care Health Diagnostics Medical Device Personal Health
Founded:
1997-01-01
Address:
Hayward, California, United States
Country:
United States
Website Url:
http://www.intarcia.com
Total Employee:
251+
Status:
Active
Contact:
617-936-2500
Email Addresses:
[email protected]
Total Funding:
1.68 B USD
Technology used in webpage:
Domain Not Resolving Euro IPv6 Amazon Route 53 Microsoft Apple Whitelist
Similar Organizations
Advanced Animal Diagnostics
Advanced Animal Diagnostics develops diagnostic products to cure on-farm animal diseases.
Aerin Medical
Aerin Medical is a health technology company that develops therapeutic devices to improve nasal breathing.
Akebia Therapeutics
Akebia Therapeutics develops treatments for ischemia and vascular diseases.
Alcresta
Alcresta develops enzyme-based nutritional products for infants and adults with acute and chronic diseases.
American Renal Associates Holdings
American Renal Associates Holdings operates kidney dialysis services and offers outpatient and inpatient dialysis treatments.
Ancora Heart
Ancora Heart is dedicated to helping people with heart failure feel better and live longer.
SpaceOAR
SpaceOAR is a medical device company that develops space-filling hydrogels for radiation oncology and cancer surgery indications.
Binx Health
Binx Health creates new categories of healthcare solutions that deliver on-demand testing to people where they need it most.
Butterfly Network
Butterfly Network designs a medical imaging device that reduces the cost of real-time and three-dimensional imaging and treatment.
Celator Pharmaceuticals
Celator Pharmaceuticals is a biopharmaceutical company developing therapies to treat cancer, using the drug ratio technology platform.
Daktari Diagnostics
Daktari Diagnostics manufactures diagnostic medical products for clinicians and patients.
Elcelyx Therapeutics
Elcelyx Therapeutics is developing nutrient sensing-based products for weight management and obesity-related metabolic disorders.
Enzium
Enzium develops fluorescent based reagents for selective protease.
Galera Therapeutics
Galera Therapeutics develops therapeutic agents for preventing damage to normal tissues during the radiation treatment of cancer.
Forward
Forward is a healthcare startup that provides a membership-based health care system.
Humacyte
Humacyte develops products for vascular diseases and replacement of anatomical conduits.
ImaginAb
ImaginAb clinically manages cancer and autoimmune diseases via molecular imaging by re-engineering antibodies into small proteins.
Impliant
Impliant, Inc. develops novel spine arthroplasty solutions for motion preservation. The company offers TOPS system.
Injectsense
Monitoring therapy effectiveness (glaucoma) through miniaturized, autonomous in-vivo sensing and data uploading to cloud database.
iPierian
iPierian is a drug discovery platform that develops therapies for neurodegenerative diseases such as SMA, ALS, and Parkinson’s.
Ivantis
Ivantis is focused on developing an innovative treatment for glaucoma which includes eye drops, laser therapy, and surgery.
jCyte
jCyte is a developer of cell-based technology intended to cure retinitis pigmentosa.
Moximed
Moximed improves the standard of care for patients with osteoarthritis and investigates therapies to treat affected joints.
Opus Genetics
Opus Genetics is a gene therapy company for ultra-rare blinding conditions.
Oxford Immunotec
Oxford Immunotec, a medical diagnostics company, develops tests for various diseases based on its innovative T cell measurement technology.
OxSonics Therapeutics
OxSonics® Therapeutics’ proprietary drug delivery platform technology, SonoTran®
Prima Temp
Prima Temp specializes in fertility detection, early disease detection, and circadian rhythm monitoring.
Amelia Virtual Care
Amelia Virtual Care develops a virtual reality platform designed to bring value to mental health treatment.
CardiacSense
CardiacSense is a developer of a wearable technology for continuous cardiac arrhythmia detection and non-inflating blood pressure monitoring
Syndevrx
SynDevRx develops polymer-based drug conjugates for small molecule drug activity.
UE LifeSciences
UE LifeSciences is a female technology company building preventive oncology solutions for primary care and home.
Unicycive Therapeutics
Unicycive Therapeutics provides development programs that focus on treating kidney diseases with unmet medical needs.
Aspira Women's Health
Aspira Women's Health develops and commercializes diagnostic tests that address unmet needs in gynecologic oncology and women’s health.
Know Labs
Know Labs is a non-invasive diagnostic technology platform that uses radio waves to identify and measure molecules in the body.
Vivos Therapeutics
Vivos Therapeutics is a medical research and development company focused on breathing wellness.
Current Advisors List
Current Employees Featured
Founder
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2015-09-24 | Phoundry Pharmaceuticals | Phoundry Pharmaceuticals acquired by Intarcia Therapeutics | N/A |
Investors List
GGV Capital
GGV Capital investment in Venture Round - Intarcia Therapeutics
SharesPost Investment Management
SharesPost Investment Management investment in Secondary Market - Intarcia Therapeutics
GWC Innovator Fund
GWC Innovator Fund investment in Series E - Intarcia Therapeutics
Bill & Melinda Gates Foundation
Bill & Melinda Gates Foundation investment in Series E - Intarcia Therapeutics
The Pritzker Organization
The Pritzker Organization investment in Series E - Intarcia Therapeutics
Foresite Capital
Foresite Capital investment in Series E - Intarcia Therapeutics
The Baupost Group
The Baupost Group investment in Series E - Intarcia Therapeutics
RA Capital Management
RA Capital Management investment in Series E - Intarcia Therapeutics
Baillie Gifford
Baillie Gifford investment in Series E - Intarcia Therapeutics
Kayon Partners
Kayon Partners investment in Series E - Intarcia Therapeutics
Official Site Inspections
http://www.intarcia.com
- Host name: ec2-18-208-125-27.compute-1.amazonaws.com
- IP address: 18.208.125.27
- Location: Ashburn United States
- Latitude: 39.0481
- Longitude: -77.4728
- Metro Code: 511
- Timezone: America/New_York
- Postal: 20149
More informations about "Intarcia Therapeutics"
Intarcia Therapeutics - Wikipedia
Intarcia Therapeutics is an American biopharmaceutical company based in Boston, MA and incorporated under the laws of Delaware. It was founded in 1995 under the name "BioMedicines" and changed to its present name in 2004. In 2013, Intarcia relocated its headquarters to Boston, keeping its manufacturing facility in Hayward, CA. In addition to Boston and Hayward, Intarcia also has a location in Research Triangle Park, North Carolina, where it discovers and develops …See details»
Intarcia Company Profile 2024: Valuation, Funding
Intarcia General Information Description. Developer of drug therapies intended to deliver an improved therapeutic outcome while enhancing patients' quality of life. The company's proprietary subcutaneous delivery system comprises three …See details»
Intarcia Therapeutics, Inc. Company Profile | Cambridge, MA ...
Intarcia Therapeutics, Inc. is a biopharmaceutical company dedicated to improving real-world adherence and real-world outcomes by leveraging the convergence of medicines and novel …See details»
Intarcia Therapeutics - Funding, Financials, Valuation & Investors
Sep 24, 2015 Intarcia Therapeutics is funded by 27 investors. Notable Capital and SharesPost Investment Management are the most recent investors. Intarcia Therapeutics has a post …See details»
Intarcia Therapeutics, Inc. - LinkedIn
Intarcia Therapeutics, Inc. | 11,793 followers on LinkedIn. We operate with a “No Analog” mindset—continually pushing boundaries, navigating new terrain and unleashing fresh thinking. We are ...See details»
Intarcia Therapeutics, Inc. - Devex
Intarcia Therapeutics, Inc., is a rapidly emerging biopharmaceutical company committed to developing innovative therapies utilizing the Medici Drug Delivery System™ – medicines that …See details»
Intarcia Therapeutics - Contacts, Employees, Board Members, …
Organization. Intarcia Therapeutics . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. ... Number of Board Member and Advisor Profiles 7. Contacts …See details»
Intarcia Therapeutics - Craft
Intarcia Therapeutics is a biopharmaceutical company developing therapies for chronic diseases. Its flagship product, Medici Drug Delivery System, aims to transform the prevention and …See details»
Intarcia Therapeutics CEO and Key Executive Team | Craft.co
Intarcia Therapeutics's Chairman, President and CEO is Kurt Graves. Other executives include Bryan Roberts, Director; Thomas Alessi, Vice President, Development and Manufacturing and …See details»
Intarcia, a former biotech unicorn, gets new life with startup deal
Aug 30, 2023 Former biotechnology unicorn Intarcia Therapeutics is getting a new life less than a month before a panel of Food and Drug Administration advisers could decide the fate of the …See details»
FDA offers former biotech unicorn Intarcia a chance for a panel …
Feb 9, 2023 Intarcia was one of the high-flying companies that emerged from the investment money that flooded into small biotechnology companies in the 2010s. Its strategy was to …See details»
Intarcia Therapeutics Secures Landmark $210 Million Financing To …
Nov 15, 2012 The World Health Organization estimates deaths resulting from diabetes will double between 2005 and 2030 and estimates the global cost of diabetes to have exceeded …See details»
Intarcia, a failed diabetes "unicorn," could be resurrected - Axios
Sep 20, 2023 But Intarcia's initial submission, which comically exceeded 1 million pages, was rejected by the FDA in late 2017 because of both product manufacturing quality concerns and …See details»
Intarcia faces FDA refusal to approve as push to get diabetes …
Sep 7, 2021 Intarcia Therapeutics has hit another roadblock at the FDA in its effort to win approval for a GLP-1 delivery system. After issuing two complete response letters and denying …See details»
Mission, Vision & Core Values of Intarcia Therapeutics
Oct 2, 2024 Intarcia Therapeutics Mission, Vision & Core Values - At Intarcia Therapeutics, our mission is to revolutionize the way chronic diseases are managed through groundbreaking …See details»
Intarcia Therapeutics Takes One Last Shot at FDA Approval
Nov 22, 2021 Just last year, Intarcia had more than 300 employees and was valued at $4.2 billion on the promise of a matchstick-sized implant that delivers the Type 2 diabetes medicine …See details»
What happens when a unicorn falls? - The Boston Globe
Oct 10, 2021 Intarcia planned to use a matchstick-size metal device, inserted under a patient’s skin to deliver six months’ worth of a drug that reduces sugar levels in the blood, exenatide.See details»
ITCA 650 | Clinical Diabetes - American Diabetes Association
Jul 1, 2018 Intarcia does not expect that new trials will be needed to satisfy FDA requests, and with transparent guidance provided by the agency, Intarcia’s ITCA 650 is on a clear path …See details»
Once valued at more than $5B, Intarcia Therapeutics sees all of its ...
Aug 31, 2022 Once valued at more than $5B, Intarcia Therapeutics sees all of its execs depart and its final shot at FDA deniedSee details»